Hospital
Ochsner Medical Center - Kenner, L.L.C.
Ochsner Medical Center - Kenner, L.L.C. was paid $25.00M by Medicaid between Jan 2018 and Dec 2024, across 151 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoOCHSNER MEDICAL CENTER - KENNER, L.L.C.
KENNER, LA 70065
KENNER, LA 70065
33aNPI1710097936assigned 08/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.00M
24GClaims630,081
24DCodes billed151
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#19 of 96
Median peer was paid$5.17M
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,421 | $2.53M | |
| 2019 | 75,664 | $2.88M | |
| 2020 | 63,092 | $2.25M | |
| 2021 | 98,602 | $3.86M | |
| 2022 | 116,815 | $4.83M | |
| 2023 | 125,226 | $4.96M | |
| 2024incomplete | 82,261 | $3.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 70,719 | 65,275 | $8.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 53,537 | 50,203 | $4.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 24,933 | 22,629 | $4.16M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.6% | 18,478 | 16,951 | $1.15M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.2% | 26,842 | 24,749 | $1.05M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.7% | 12,573 | 11,741 | $436K |
| 80053 | Comprehensive metabolic panel | 1.7% | 54,662 | 48,276 | $413K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 6,384 | 5,922 | $380K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 61,212 | 53,650 | $341K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 22,498 | 20,354 | $329K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 17,387 | 14,606 | $326K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 17,068 | 14,553 | $313K |
139 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 1.1% | 5,580 | $285K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 854 | $234K |
| 81025 | <1% | 32,920 | $218K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,778 | $192K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,220 | $161K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,550 | $155K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,152 | $151K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,745 | $146K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,265 | $110K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,776 | $99K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 992 | $71K |
| 80050 | General health panel | <1% | 1,798 | $71K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,389 | $68K |
| 84484 | <1% | 8,151 | $63K | |
| 81000 | <1% | 21,655 | $61K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,986 | $55K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,263 | $50K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,532 | $49K |
| 80061 | Lipid panel | <1% | 4,179 | $48K |
| 59025 | Fetal non-stress test | <1% | 427 | $35K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 179 | $28K |
| 86703 | <1% | 2,371 | $26K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,951 | $26K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,345 | $25K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 474 | $24K |
| 83690 | <1% | 4,571 | $23K | |
| 82607 | <1% | 1,681 | $23K | |
| 86803 | <1% | 1,628 | $22K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,517 | $21K |
| G0378 | Hospital observation service, per hour | <1% | 330 | $19K |
| 80074 | <1% | 639 | $18K | |
| 83880 | <1% | 745 | $18K | |
| 81003 | <1% | 10,163 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 735 | $17K |
| 87400 | <1% | 2,138 | $16K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 581 | $15K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 190 | $15K |
| 82728 | <1% | 1,218 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 429 | $14K |
| 83021 | <1% | 914 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 556 | $13K |
| 86592 | <1% | 3,308 | $13K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 256 | $11K |
| 87081 | <1% | 1,640 | $11K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 177 | $11K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 167 | $10K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,346 | $10K |
| 83020 | <1% | 992 | $10K | |
| 87340 | <1% | 1,124 | $10K | |
| 87634 | <1% | 165 | $10K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 275 | $9K |
| 73564 | <1% | 277 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,132 | $9K |
| 84466 | <1% | 809 | $8K | |
| 83735 | <1% | 2,064 | $8K | |
| 80055 | <1% | 407 | $8K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 130 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 357 | $7K |
| 84439 | <1% | 754 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 78 | $5K |
| 85027 | <1% | 1,132 | $5K | |
| 82950 | <1% | 980 | $4K | |
| 83540 | <1% | 823 | $4K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 28 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 338 | $4K |
| 86762 | <1% | 325 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 50 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $4K |
| 73630 | <1% | 186 | $4K | |
| 86200 | <1% | 286 | $3K | |
| 84550 | <1% | 954 | $3K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 93 | $3K |
| 86850 | <1% | 614 | $3K | |
| 74019 | <1% | 80 | $3K | |
| 86593 | <1% | 738 | $3K | |
| 84702 | <1% | 208 | $3K | |
| 86696 | <1% | 131 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 59 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,038 | $2K |
| 86038 | <1% | 181 | $2K | |
| 82962 | <1% | 848 | $2K | |
| 83970 | <1% | 131 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,004 | $2K |
| 87807 | <1% | 149 | $2K | |
| 86695 | <1% | 130 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 836 | $2K |
| 73030 | <1% | 54 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 228 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 48 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 247 | $1K |
| 86901 | <1% | 617 | $1K | |
| 86900 | <1% | 612 | $1K | |
| 80069 | <1% | 278 | $1K | |
| 84153 | <1% | 68 | $1K | |
| 73562 | <1% | 52 | $1K | |
| 82570 | <1% | 275 | $1K | |
| 82043 | <1% | 204 | $952.63 | |
| 84100 | <1% | 334 | $949.74 | |
| 94760 | <1% | 131 | $948.62 | |
| 80081 | <1% | 15 | $920.82 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 206 | $662.51 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 320 | $415.96 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $378.72 |
| 80076 | <1% | 47 | $350.14 | |
| 86706 | <1% | 36 | $335.90 | |
| 83921 | <1% | 15 | $300.76 | |
| 85610 | <1% | 89 | $276.82 | |
| 86140 | <1% | 72 | $269.16 | |
| 81511 | <1% | 25 | $266.55 | |
| 84154 | <1% | 13 | $224.92 | |
| 90686 | <1% | 46 | $207.12 | |
| 82550 | <1% | 42 | $198.14 | |
| 80320 | <1% | 14 | $190.19 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 102 | $187.16 |
| 87070 | <1% | 51 | $148.50 | |
| 94761 | <1% | 15 | $138.21 | |
| 87075 | <1% | 39 | $124.63 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 13 | $121.80 |
| 85379 | <1% | 14 | $113.91 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 75 | $92.96 |
| 83605 | <1% | 15 | $82.38 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 73 | $72.31 |
| 82150 | <1% | 12 | $65.82 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 32 | $58.95 |
| J2704 | Injection, propofol, 10 mg | <1% | 875 | $54.46 |
| 82803 | <1% | 14 | $50.38 | |
| 85652 | <1% | 28 | $46.74 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 15 | $30.59 |
| 84156 | <1% | 27 | $30.13 | |
| 99152 | <1% | 19 | $20.78 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 36 | $9.66 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 64 | $4.33 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 241 | $4.33 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 181 | $2.72 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 75 | $2.14 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 41 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 113 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 89 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNOVEMBER, PETER (EVP AND CFO)
| Provider | Location | Paid |
|---|---|---|
| Ochsner Clinic Foundation | New Orleans, LA | $166.97M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.